Skip to main content
Quest Diagnostics

Clinical Utility of Structural Variant Calling Using Breakpoint Analysis Method for Targeted NGS Gene Panels

ACMG Annual Clinical Genetics Meeting, 2024

American College of Medical Genetics and Genomics

Toronto, Canada, March 12-16, 2024

Poster presentation: Clinical utility of structural variant calling using breakpoint analysis method for targeted NGS gene panels

Authors: Andreevskaya M, Muona M, Koskinen L*, Pietilä T, Djupsjöbacka J, Kytölä V, Kämpjärvi K, Myllykangas S, Salmenperä P, Koskenvuo J, Valori M

Specialty: Genetics

Disclaimer: One or more of the authors of this abstract were employed at the time by BluePrint Genetics, a subsidiary of Quest Diagnostics.

Related content

Publication
Diagnostic utility of next-generation sequencing-based panel testing in 543 patients with suspected skeletal dysplasia
The Utility of Exome Sequencing for Neurodevelopmental Disorders at a Large Reference Laboratory
Conference Presentation
Diagnostic Utility of Next-Generation Sequencing Panel Tests in the Diagnosis of Skeletal Dysplasias
Conference Presentation
Diagnostic Utility of Next-Generation Sequencing Panel Tests in the Diagnosis of Skeletal Dysplasias
Audio Podcast
The power of laboratory analytics

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.